Christopher T Rankin

Address:

6523 79 Pl, Cabin John, MD 20818

VIN:

YV1MC68297J023504

Make:

Volvo

Model:

C70

Year:

2007

US Patent:

7355008, Apr 8, 2008

Filed:

Jan 9, 2004

Appl. No.:

10/754922

Inventors:

Jeffrey Stavenhagen - Brookville MD, US
Sujata Vijh - Gaithersburg MD, US
Christopher Rankin - Clarksburg MD, US
Sergey Gorlatov - Gaithersburg MD, US
Ling Huang - Gaithersburg MD, US

Assignee:

Macrogenics, Inc. - Rockville MD

International Classification:

C07K 16/00
C12P 21/08
C07K 1/00

US Classification:

5303871, 5303873, 5303877

Abstract:

The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e. g. , antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e. g. , ADCC) mediated by FcγR is desired, e. g. , cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

US Patent:

7960512, Jun 14, 2011

Filed:

Jul 28, 2004

Appl. No.:

10/902588

Inventors:

Jeffrey Stavenhagen - Brookville MD, US
Sujata Vijh - Gaithersburg MD, US
Christopher Rankin - Clarksburg MD, US
Sergey Gorlatov - Gaithersburg MD, US
Ling Huang - Gaithersburg MD, US

Assignee:

MacroGenics, Inc. - Rockville MD

International Classification:

C12P 21/08
C07K 16/00
C07K 17/00

US Classification:

5303871, 5303873, 5303881

Abstract:

The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e. g. , antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e. g. , ADCC) mediated by FcγR is desired, e. g. , cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

US Patent:

8003774, Aug 23, 2011

Filed:

Jan 30, 2008

Appl. No.:

12/022762

Inventors:

Jeffrey B. Stavenhagen - Brookville MD, US
Sujata Vijh - Gaithersburg MD, US
Christopher Rankin - Clarksburg MD, US
Sergey Gorlatov - Gaithersburg MD, US
Ling Huang - Gaithersburg MD, US

Assignee:

MacroGenics, Inc. - Rockville MD

International Classification:

C07H 21/04
C12P 21/06
C12N 15/09
C12N 1/20
C12N 5/00
C12N 5/16
C12N 15/00

US Classification:

536 2353, 435 691, 435 696, 435440, 435455, 435325, 435326, 435328, 435330, 435331, 4352523, 4353201

Abstract:

The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e. g. , antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e. g. , ADCC) mediated by FcγR is desired, e. g. , cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

US Patent:

8192737, Jun 5, 2012

Filed:

Jan 30, 2008

Appl. No.:

12/022772

Inventors:

Jeffrey B. Stavenhagen - Brookville MD, US
Sujata Vijh - Gaithersburg MD, US
Christopher Rankin - Clarksburg MD, US

Assignee:

MacroGenics, Inc. - Rockville MD

International Classification:

A61K 39/395
C07K 16/00

US Classification:

4241301, 4241321, 4241331, 4241381, 4241411

Abstract:

The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e. g. , antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e. g. , ADCC) mediated by FcγR is desired, e. g. , cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

US Patent:

8217147, Jul 10, 2012

Filed:

Aug 10, 2006

Appl. No.:

11/502820

Inventors:

Jeffrey Stavenhagen - Brookville MD, US
Sergey Gorlatov - Gaithersburg MD, US
Christopher Rankin - Clarksburg MD, US
Nadine Tuaillon - Gaithersburg PA, US

Assignee:

MacroGenics, Inc. - Rockville MD

International Classification:

C07K 16/00
C12P 21/08
C07H 21/04
C12Q 1/68
C12N 15/00
C12N 5/16
C07K 17/00

US Classification:

5303871, 5303873, 5303881, 435 6, 4353201, 435326, 536 2353

Abstract:

The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e. g. , antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e. g. , ADCC) mediated by FcγR is desired, e. g. , cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

US Patent:

8445645, May 21, 2013

Filed:

Jun 10, 2011

Appl. No.:

13/158169

Inventors:

Jeffrey Stavenhagen - Brookville MD, US
Sujata Vijh - Gaithersburg MD, US
Christopher Rankin - Clarksburg MD, US
Sergey Gorlatov - Gaithersburg MD, US
Ling Huang - Gaithersburg MD, US

Assignee:

MacroGenics, Inc. - Rockville MD

International Classification:

C07K 16/00
C12P 21/08
A61K 39/395
A61K 39/40

US Classification:

5303871, 5303873, 5303881, 53038822, 5303887, 4241301, 4241331, 4241341, 4241411, 4241441, 4241521, 4241531

Abstract:

The present invention relates to molecules, particularly polypeptides, more particularly immunoglobulins (e. g. , antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region, which variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection. The molecules of the invention are particularly useful for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function (e. g. , ADCC) mediated by FcγR is desired, e. g. , cancer, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

US Patent:

20030023073, Jan 30, 2003

Filed:

Jul 12, 2002

Appl. No.:

10/194382

Inventors:

Se-Jin Lee - Baltimore MD, US
Thanh Huynh - Baltimore MD, US
Suzanne Sebald - Jessup MD, US
Christopher Rankin - Columbia MD, US
Edward Hsiao - Baltimore MD, US

Assignee:

The Johns Hopkins University School of Medicine

International Classification:

C07K014/575
C07H021/04
C12P021/02
C12N001/21

US Classification:

536/023500, 530/399000, 435/069400, 435/320100, 435/252300

Abstract:

Growth differentiation factor-15 (GDF-15) polynucleotide sequence and amino acid sequence are provided herein. Also described are diagnostic and therapeutic methods of using GDF-15 polypeptide and polynucleotide sequences.

US Patent:

20050260213, Nov 24, 2005

Filed:

Apr 15, 2005

Appl. No.:

11/108135

Inventors:

Scott Koenig - Rockville MD, US
Maria Veri - Denwood MD, US
Nadine Tuaillon - Gettysburg PA, US
Ezio Bonvini - Rockville MD, US
Jeffrey Stavenhagen - Brookville MD, US
Christopher Rankin - Clarksburg MD, US

International Classification:

A61K039/395
C07K016/46

US Classification:

424178100, 530391100

Abstract:

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The present invention also provides the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.